The “Next Bitcoin”? 10 CENT Crypto Set to Explode

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Richard Chin Biography and Net Worth

CEO of Kindred Biosciences

Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Drugs Richard developed, including Lucentis®, Xolair®, Tysabri®, and Rituxan® for immune diseases, have current aggregate sales of well over $10 billion per year.

Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw all of Genentech’s drug development programs except oncology products; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. Richard was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.

What is Richard Chin's net worth?: The estimated net worth of Richard Chin is at least $14.56 million as of August 2nd, 2021. Dr. Chin owns 1,574,271 shares of Kindred Biosciences stock worth more than $14,562,007 as of April 26th. This net worth estimate does not reflect any other assets that Dr. Chin may own. Learn More about Richard Chin's net worth.
How do I contact Richard Chin?: The corporate mailing address for Dr. Chin and other Kindred Biosciences executives is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. Kindred Biosciences can also be reached via phone at (650) 701-7901 and via email at [email protected]. Learn More on Richard Chin's contact information.
Has Richard Chin been buying or selling shares of Kindred Biosciences?: Richard Chin has not been actively trading shares of Kindred Biosciences during the last ninety days. Most recently, Richard Chin sold 40,000 shares of the business's stock in a transaction on Monday, August 2nd. The shares were sold at an average price of $9.21, for a transaction totalling $368,400.00. Following the completion of the sale, the chief executive officer now directly owns 1,574,271 shares of the company's stock, valued at $14,499,035.91. Learn More on Richard Chin's trading history.

Richard Chin Insider Trading History at Kindred Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/2/2021	Sell	40,000	$9.21	$368,400.00	1,574,271
7/2/2021	Sell	40,000	$9.18	$367,200.00	1,894,271
6/16/2021	Sell	40,000	$9.18	$367,200.00	1,934,271
1/2/2019	Sell	40,000	$10.57	$422,800.00	1,906,071
12/3/2018	Sell	40,000	$13.28	$531,200.00	1,946,071
11/1/2018	Sell	40,000	$14.68	$587,200.00	1,986,071
10/1/2018	Sell	40,000	$13.28	$531,200.00	2,026,071
9/5/2018	Sell	40,000	$14.79	$591,600.00	2,073,671
8/1/2018	Sell	40,000	$13.51	$540,400.00	2,106,071
7/2/2018	Sell	40,000	$10.28	$411,200.00	2,146,071
6/1/2018	Sell	40,000	$10.13	$405,200.00	2,226,071
5/30/2018	Sell	12,610	$10.00	$126,100.00	2,226,071
5/25/2018	Sell	3,060	$10.00	$30,600.00	2,241,681
5/18/2018	Sell	2,400	$10.00	$24,000.00	2,241,741
5/9/2018	Sell	1,930	$10.01	$19,319.30	2,244,341
5/7/2018	Sell	1,730	$10.01	$17,317.30	2,244,341
5/1/2018	Sell	20,000	$9.05	$181,000.00	2,246,071
4/2/2018	Sell	20,000	$8.39	$167,800.00	2,266,071
7/3/2017	Sell	13,000	$8.26	$107,380.00	2,297,546
6/22/2017	Sell	13,000	$7.75	$100,750.00	2,310,546

Richard Chin Buying and Selling Activity at Kindred Biosciences

Kindred Biosciences Company Overview

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Today's Range

Now: $9.25

$9.24

$9.26

50 Day Range

MA: $9.22

$9.08

$9.25

2 Week Range

Now: $9.25

$3.46

$9.28

Volume

178,496 shs

Average Volume

840,890 shs

Market Capitalization

$420.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3